Clinical status of agents being developed for leishmaniasis

Expert Opinion on Investigational Drugs

Volumn 14, Issue 11, 2005, Pages 1337-1346

  Berman, Jonathan ^a  

^a National Institutes of Health   (United States)

Author keywords

Fluconazole; Imiquimod; Leishmaniasis; Miltefosine; Paromomycin; Sitamaquine

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; ANTIMONY DERIVATIVE; FLUCONAZOLE; IMIQUIMOD; ITRACONAZOLE; KETOCONAZOLE; LIVER ENZYME; MEGLUMINE ANTIMONATE; METHYLBENZETHONIUM CHLORIDE; MILTEFOSINE; PARAFFIN; PAROMOMYCIN; PENTAMIDINE; PLACEBO; SITAMAQUINE; STIBOGLUCONATE SODIUM; TERBINAFINE; UREA;

ANOREXIA; ARTHRALGIA; CHILL; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; ENZYME DEFECT; FEVER; HEALTH CARE COST; HEALTH CARE NEED; HUMAN; HYPERAMYLASEMIA; KIDNEY DYSFUNCTION; LEISHMANIA MAJOR; LEISHMANIASIS; MALE INFERTILITY; METHEMOGLOBINEMIA; MYALGIA; NEPHROTOXICITY; NONHUMAN; REVIEW; SAUDI ARABIA; SKIN; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS; VOMITING;

AMINOQUINOLINES; ANTIPROTOZOAL AGENTS; FLUCONAZOLE; HUMANS; KETOCONAZOLE; LEISHMANIASIS; PAROMOMYCIN; PHOSPHORYLCHOLINE;

EID: 27744451508     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.11.1337     Document Type: Review

References (56)

1. ASHFORD RW, DESJEUX P, DERAADT P: Estimation and population at risk of infection and number of cases of leishmaniasis. Parasitol. Today (1992) 8:104-105.
2. ALRAJHI AA, IBRAHIM EA, DE VOL EB, KHAIRAT M, FARIS RM, MAGUIRE JH: Fluconazole for the treatment of cutanoues leishmaniasis caused by Leishmania major. N. Engl. J. Med. (2002) 346:891-895.
3. HERWALDT BL, ARANA BA, NAVIN TR: The natural history of cutaneous leishmaniasis in Guatemala. J. Infect. Dis. (1992) 165:518-527.
4. SOTO J, ARANA BA, TOLEDO J et al.: Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. (2004) 38:1266-1272.
5. SUNDAR S, JHA TK, THAKUR CP et al.: Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. (2002) 347:1739-1746.
6. SUNDAR S, ROSENKAIMER F, MAKHARIA MK et al.: Trial of oral miltefosine for visceral leishmaniasis. Lancet (1998) 352:1821-1823.
7. JHA TK, SUNDAR S, THAKUR CP et al.: Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N. Engl. J. Med. (1999) 341:1795-1800.
8. BHATTACHARYA SK, JHA TK, SUNDAR S et al.: Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin. Infect. Dis. (2004) 38:217-221.
9. SINDERMANN H, ENGEL KR, FISCHER C et al.: Oral miltefosine for Leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin. Infect. Dis. (2004) 39:1520-1523.
10. SOTO J, ARANA BA, TOLEDO J et al.: Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis. (2004) 38:1266-1272.
11. HERWALDT BL: Miltefosine - the long-awaited therapy for visceral leishmaniasis? N. Engl. J. Med. (1999) 341:1840-1842.
12. SHERWOOD JA, GACHIHI GS, MUIGAI RK et al.: Phase II efficacy trial of an oral 8-aminoquinoline (WR6026) for treatment of visceral leishmaniasis. Clin. Infect. Dis. (1994) 19:1034-1039.
13. DIETZE R, CARVALHO SF, VALLI LC et al.: Phase II trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by Leishmania chagasi. Am. J. Trop. Med. Hyg. (2001) 65:685-689.
14. PETTY BG, BLACK JR, HENDRIX CW et al.: Escalating multiple-dose safety and tolerance study of oral WR 6026 in HIV-infected subjects: AIDS clinical trials group 173. J. Acquir. Immune Defic. Syndr. (1999) 21:26-32.
15. RASHID JR, NYAKUNDI PM, KIRIGI G, KINOTI D, WASUNNA MK: Compassionate use of sitamaquine in an HIV-positive patient with visceral leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. (2002) 96:533-534.
16. BERMAN JD: Activity of imidazoles against Leishmania tropica in human macrophage cultures. Am. J. Trop. Med. Hyg. (1981) 30:566-569.
17. BERMAN JD, GOAD LJ, BEACH DH, HOLZ GG Jr: Effects of ketoconazole on sterol biosynthesis by Leishmania mexicana mexicana amastigotes in murine macrophage tumor cells. Mol. Biochem. Parasitol. (1986) 20:85-92.
18. SAENZ RE, PAZ H, BERMAN JD: Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am. J. Med. (1990) 89:147-155.
19. ALSALEH QA, DVORAK R, NANDA A: Ketoconazole in the treatment of cutaneous leishmaniasis in Kuwait. Int. J. Dermatol. (1995) 34:495-497.
20. SINGH S, SINGH R, SUNDAR S: Failure of ketoconazole in oriental sore in India. J. Chemother. (1995) 7(Suppl. 4):202-203.
21. WALI JP, AGGARWAL P, NANDY A et al.: Efficacy of sodium antimony gluconate and ketoconazole in the treatment of kala-azar - a comparative study. J. Commun. Dis. (1997) 29:73-83.
22. LAFFITTE E, GENTON B, PANIZZON RG. Cutaneous leishmaniasis caused by Leishmania tropica: treatment with oral fluconazole. Dermatology (2005) 210:249-251.
23. BARON S, LAUBE S, RAAFAT F, MOSS C: Cutaneous leishmaniasis in a Kosovan child treated with oral fluconazole. Clin. Exp. Dermatol. (2004) 29:546-547.
24. SUNDAR S, SINGH VP, AGRAWAL NK, GIBBS DL, MURRAY HW: Treatment of kala-azar with oral fluconazole. Lancet (1996) 348:614.
25. JHA BB: Fluconazole in visceral leishmaniasis. Indian Pediatr. (1998) 35:268-269.
26. TORRUS D, BOIX V, MASSA B, PORTILLA J, PEREZ-MATEO M: Fluconazole plus allopurinol in treatment of visceral leishmaniasis. J. Antimicrob. Chemother. (1996) 37:1042-1043.
27. SOTO-MANCIPE J, GROGL M, BERMAN JD: Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin. Infect. Dis. (1993) 16:417-425.
28. CALVOPINA M, GUEVARA AG, ARMIJOS RX, HASHIGUCHI Y, DAVIDSON RN, COOPER PJ: Itraconazole in the treatment of New World mucocutaneous leishmaniasis. Int. J. Dermatol. (2004) 43:659-663.
29. NASSIRI-KASHANI M, FIROOZ A, KHAMESIPOUR A et al.: A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J. Eur. Acad. Dermatol. Venereol. (2005) 19:80-83.
30. KHALIL EA, NUR NM, ZIJLSTRA EE, EL-HASSAN AM, DAVIDSON RN: Failure of a combination of two antifungal drugs, terbinafine plus itraconazole, in Sudanese post kala-azar dermal leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. (1996) 90:187-188.
31. DOGRA J, SAXENA VN: Itraconazole and leishmaniasis: a randomised double-blind trial in cutaneous disease. Int. J. Parasitol. (1996) 26:1413-1415.
32. MARTINEZ S, MARR JJ: Allopurinol in the treatment of American cutaneous leishmaniasis. N. Engl J. Med. (1992) 326:741-744.
33. VELEZ I, AGUDELO S, HENDRICKX E et al.: Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann. Intern. Med. (1997) 126:232-236.
34. MARTINEZ S, GONZALEZ M, VERNAZA ME: Treatment of cutaneous leishmaniasis with allopurinol and stibogluconate. Clin. Infect. Dis. (1997) 24:165-169.
35. LLANOS-CUENTAS A, ECHEVARRIA J, CRUZ M et al.: Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis. Clin. Infect. Dis. (1997) 25:677-684.
36. MOMENI AZ, AMINJAVAHERI M: Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol. Eur. J. Dermatol. (2003) 13:40-43.
37. EL-ON J, HALEVY S, GRUNWALD MH, WEINRAUCH L: Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: a double-blind control study. J. Am. Acad. Dermatol. (1992) 27:227-231.
38. SALAH A, ZAKRAOUI H, ZAATOUR A et al.: A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am. J. Trop. Med. Hyg. (1995) 53:162-166.
39. ASILIAN A, JALAYER T, WHITWORTH JA, GHASEMI RL, NILFOROOSHZADEH M, OLLIARO P: A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am. J. Trop. Med. Hyg. (1995) 53:648-651.
40. ASILIAN A, JALAYER T, NILFOROOSHZADEH M et al.: Treatment of cutaneous leishmaniasis with aminosidine (paromomycin) ointment: double-blind, randomized trial in the Islamic Republic of Iran. Bull. World Health Organ. (2003) 81:353-359.
41. FAGHIHI G, TAVAKOLI-KIA R: Treatment of cutaneous leishmaniasis with either topical paromomycin or intralesional meglumine antimoniate. Clin. Exp. Dermatol. (2003) 28:13-16.
42. SHAZAD B, ABBASZADEH B, KHAMESIPOUR A: Comparison of topical paromomycin sulfate (twice/day) with intralesional meglumine antimoniate for the treatment of cutaneous leishmaniasis caused by L. major. Eur. J. Dermatol. (2005) 15:85-87.
43. SOTO J, FUYA P, HERRERA R, BERMAN J: Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin. Infect. Dis. (1998) 26:56-58.
44. ARMIJOS RX, WEIGEL MM, CALVOPINA M, MANCHENO M, RODRIGUEZ R: Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop. (2004) 91:153-160.
45. ARANA BA, MENDOZA CE, RIZZO NR, KROEGER A: Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am. J. Trop. Med. Hyg. (2001) 65:466-470.
46. SOTO JM, TOLEDO JT, GUTIERREZ P et al.: Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): Phase II pilot study. Am. J. Trop. Med. Hyg. (2002) 66:147-151.
47. AREVALO I, WARD B, MILLER R et al.: Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin. Infect. Dis. (2001) 33:1847-1851.
48. MIRANDA-VERASTEGUI C, LLANOS-CUENTAS A, AREVALO I, WARD BJ, MATLASHEWSKI G: Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru. Clin. Infect. Dis. (2005) 40:1395-1403
49. SEEBERGER J, DAOUD S, PAMMER J: Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int. J. Dermatol. (2003) 42:576-579.
50. CHUNGE CN, OWATE J, PAMBA HO, DONNO L: Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg. (1990) 84:221-225.
51. THAKUR CP, OLLIARO P, GOTHOSKAR S et al.: Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans. R. Soc. Trop. Med. Hyg (1992) 86:615-616.
52. SEAMAN J, PRYCE D, SONDORP HE, MOODY A, BRYCESON AD, DAVIDSON RN: Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J. Infect. Dis. (1993) 168:715-720.
53. JHA TK, OLLIARO P, THAKUR CP et al.: Randomized controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. Br. Med. J. (1998) 316:1200-1205
54. THAKUR CP, KANYOK TP, PANDEY AK, SINHA GP, MESSICK C, OLLIARO P: Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized Phase-II clinical study. Trans. R. Soc. Trop. Med. Hyg. (2000) 94:432-433.
55. SOTO J, GROGL M, BERMAN J, OLLIARO P: Limited efficacy of injectable aminosidine as single-agent therapy for Colombian cutaneous leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. (1994) 88:695-698.
56. HEPBURN NC, TIDMAN MJ, HUNTER JA: Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg. (1994) 88:700-703.